Menu
Back to Journals » Infection and Drug Resistance » Volume 11
Better drugs for Lyme disease: focus on the spirochete
Authors Stricker RB, Middelveen MJ
Received 11 June 2018
Accepted for publication 20 July 2018
Published 7 September 2018 Volume 2018:11 Pages 1437—1439
DOI https://doi.org/10.2147/IDR.S176831
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Suresh Antony
Video abstract presented by Raphael Stricker.
Views: 505
Raphael B Stricker,1 Marianne J Middelveen2
1Union Square Medical Associates, San Francisco, CA, USA; 2Atkins Veterinary Services, Calgary, AB, Canada
Abstract: Twenty-five years ago, the AIDS epidemic was wreaking havoc around the world. Although “HIV denialists” threatened to undermine research efforts to combat the epidemic, development of targeted antiviral therapy eventually provided effective treatment for the disease. Now the Lyme disease epidemic is wreaking havoc around the world, and “Lyme denialists” are undermining efforts to combat the epidemic. Drawing on our experience with the AIDS epidemic, there is a significant need to develop targeted therapy to control the Lyme disease epidemic.
Keywords: HIV/AIDS, Lyme disease, Borrelia burgdorferi, tick-borne disease, designer drugs
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.